7-hydroxystaurosporine has been researched along with Lymphoma, B-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujinaka, Y; Gillespie, DA; Iimori, M; Kakeji, Y; Kitao, H; Maehara, Y; Matsuoka, K; Morita, M; Saeki, H; Sakasai, R; Takata, M; Tuul, M; Yamamoto, K; Yoshinaga, K | 1 |
| Balis, FM; Bauer, K; Figg, WD; Monks, A; Mont, EK; Raffeld, M; Sausville, E; Senderowicz, AM; Sorbara, L; Warren, KE; Wilson, WH | 1 |
2 other study(ies) available for 7-hydroxystaurosporine and Lymphoma, B-Cell
| Article | Year |
|---|---|
ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Nucleus; Checkpoint Kinase 1; Chickens; Cytoprotection; DNA Breaks, Double-Stranded; Fanconi Anemia Complementation Group D2 Protein; Fluorouracil; Histones; Lymphoma, B-Cell; Mutation; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Recombinational DNA Repair; Signal Transduction; Staurosporine; Time Factors | 2012 |
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Topics: Aged; Alkaloids; Antineoplastic Agents; B-Lymphocytes; Drug Resistance, Neoplasm; Humans; Lymph Nodes; Lymphoma, B-Cell; Male; Neoplasm Staging; Protein Kinase C; Staurosporine; T-Lymphocytes; Tissue Distribution | 2000 |